New hope for kids: experimental combo aims to stop dangerous transplant complication
NCT ID NCT07350057
Summary
This early-stage study is testing whether adding a new oral drug called VIC-1911 to two existing medications can safely prevent graft-versus-host disease (GVHD) in children. GVHD is a serious complication where donor immune cells attack the patient's body after a half-matched stem cell transplant. The trial will first find the safest dose of VIC-1911 and then see how well the three-drug combination works to control this condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVHD (ACUTE OR CHRONIC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.